Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe

NCT03071055 is registered in ClinicalTrials.gov with Southeast Clinical Research Associates, LLC as lead sponsor.

NCT NCT03071055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03071055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe
Lead sponsor
Southeast Clinical Research Associates, LLC
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2017
Completion date
June 3, 2019
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

exudative age related macular degeneration